中国实用内科杂志2017，Vol.37Issue(3)：203-206,4.DOI:10.19538/j.nk2017030106
糖尿病肾病临床分子标志物研究进展
Research progress in molecular biomarkers of diabetic nephropathy
蒋松1
作者信息
- 1. 国家肾脏疾病临床医学研究中心南京总医院南京大学医学院,江苏南京210016
- 折叠
摘要
Abstract
Diabetes nephropathy (DN) is a major cause of end-stage renal disease (ESRD) and it accounted for 25％-45％ ofthe dialysis population.About 30％-40％ of type 1 diabetes and about 30％ of type 2 diabetes patients will eventually develop into kidney disease.Although DN has been traditionally diagnosed on the basis of measurement of UAE or GFR,many investigators are searching for alternative or additional measurements to more closely stage and predict the development and progression of DN.New investigation approaches included based on multi-omics studies have been widely used in exploring novel biomarkers of DN.Novel biomarkers may be utilized to establish molecular diagnosis system of DN,and aid in improving renal risk stratification and provide effective therapeutic target.Despite significant numbers of new biomarkers described,most studies are limited by either their small sample size or their crosssectional nature,so that the ability to predict future and severity of DN is still lacking.The review summarized recent researches on biomarker studies of DN and the related study strategy for biomarkers in DN.关键词
糖尿病肾病/组学/分子标志物Key words
diabetic nephropathy/omics/biomarke分类
医药卫生引用本文复制引用
蒋松..糖尿病肾病临床分子标志物研究进展[J].中国实用内科杂志,2017,37(3):203-206,4.
